Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-2 Pulsed DC Vaccine in High Risk Breast Cancer
NCT02063724Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2014
- Primary completion
- Sep 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of her2 peptide-pulsed dendritic cells in breast cancer, sponsored by Moffitt Cancer Center. Primary endpoint: Rate of Treatment Regimen Completion at 12 months. Started Oct 2014; status: completed.
02
Drugs
her2 peptide-pulsed dendritic cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02063724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063724.